Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
about
Noxa is necessary for hydrogen peroxide-induced caspase-dependent cell deathMYC and the art of microRNA maintenanceAdvances in the understanding of mechanisms and therapeutic use of bortezomibExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationThe p53 circuit boardERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cellsThe combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cellsGefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein NoxaBAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaEstrogen-mediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cellsRegulation of Noxa-mediated apoptosis in Helicobacter pylori-infected gastric epithelial cells.RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma developmentMitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.Targeting the overexpressed ROC1 induces G2 cell cycle arrest and apoptosis in esophageal cancer cellsNatural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaBMelanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition.Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.Proteasome inhibition and its therapeutic potential in multiple myelomaInduction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stressA phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitorsMultiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.E2F1-dependent oncogenic addiction of melanoma cells to MDM2.Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy.A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myelomaKLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.MYC Is a Major Determinant of Mitotic Cell Fate.Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicinHypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity.Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
P2860
Q24296352-89A5B487-F06A-49D7-93A8-84873C3D9A0FQ26825457-60F1DA8E-7E9D-4AFE-87C2-DCD6A5EB5DE6Q26849940-706DA2A5-BD23-41EE-8315-BFEF5B4DC60DQ28118450-19FCD8FD-A191-4513-9FC0-420572C7108EQ28259725-8429D16F-2EFB-4C0B-8700-C0C60A40D179Q28307506-4604C011-5B08-469C-A1DE-3A9B4C0228DBQ28476737-E06D2B70-6AF9-4C50-B293-0647E514F28EQ28484487-22F8FB26-00E5-49EE-899E-2C0CC5B98908Q28485309-C485B2A5-D482-4EF9-975F-ED9725B9B757Q28533736-74FE0702-D95B-4E4E-ADE7-9594939B811DQ28740916-037E57A5-DFA1-401F-A3EB-B623D65F939AQ30301289-EF695D31-82C7-40C6-924E-644C05C854E7Q30657002-C3ED02EB-F711-42A3-850E-61D75E001F41Q33701777-FAC50C2F-059E-422A-81F0-A1336E8788F5Q33710037-087D7966-59EC-4A6B-BCB8-5C03DD658FCDQ33775541-B6CF1926-54D7-45A3-81EC-11CC913006FDQ33822119-261BEA7B-5AB8-4CBE-82F5-424FA312ABB2Q34070935-5AB68253-BA9E-45C0-9F2D-78148B5E0F82Q34294233-F2C507CF-5B6A-4932-88E3-43CFEED59579Q34343036-FB2EEA76-7498-494C-987C-F96452D13D91Q34563600-E4844016-2359-4CB8-9A3D-8E25EDCD92D8Q34615116-D2C5A0F8-2A95-4462-BCE7-3C0D0A3F3159Q34635116-80399D33-F872-48DC-AE34-9E85BD3CEC9EQ34674973-9ACD53C0-D164-4281-BB91-8CD83BC81460Q35107469-49FE01D4-F0AD-46E7-857F-4A7A3E6ECCC2Q35125250-980867E1-80AB-4977-9D7F-DED44762495EQ35353609-EA436777-6ECB-4F22-A63D-014816C2A5FDQ35434111-4DDE247E-3468-4BC8-A964-648BE5A6EF5CQ35469778-DBCF4E76-1F5B-46E0-9501-9ED86940F78CQ35561120-0B8FA77F-51B9-49C1-A090-9B49CE8C7599Q35740455-114FCF6B-F764-4594-A3BE-4D194BF23918Q35776414-A884B7AF-C8C3-40B7-A95F-6E0F83A79971Q35836881-9F33DDF1-60D1-47EE-A18B-2219DFABCAA6Q35898987-DB76DD33-9985-4BA1-BC1C-9DF8C71CD991Q36204839-1ED42820-9969-43DF-8BA3-A29BE2019B4EQ36293819-FCAF8181-64D9-43E1-B953-E566495BCEC2Q36387115-3A4F3C97-DAC5-4DB0-A0D1-329F27CDBF62Q36467344-DE40FF46-9D9E-4168-B889-ADE8ECAC8806Q36526514-B9C99C20-ADCA-44F5-8C3E-FA86EBC3875BQ36540685-92253D29-4953-46DA-8D5C-9965F2B1994F
P2860
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@ast
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@en
type
label
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@ast
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@en
prefLabel
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@ast
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
@en
P2093
P2860
P356
P1476
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
@en
P2093
Andrzej J Jakubowiak
Arul M Chinnaiyan
Dazhong Zhuang
Marybeth Riblett
Mikhail A Nikiforov
Monique Verhaegen
Vladimir Gratchouck
Wen-Hua Tang
Yolanda Fernandez
P2860
P304
19488-19493
P356
10.1073/PNAS.0708380104
P407
P577
2007-11-27T00:00:00Z